Fig. 2.
a SELENA-SLEDAI and PGA scores by disease activity patterns over the observation period and b organ manifestations by SELENA-SLEDAI domains over the observation period by disease activity pattern. ***p < 0.001 MSK-CA vs MSK-RR; **p < 0.01 MSK-CA vs MSK-RR; *p < 0.05 MSK-CA vs MSK-RR; †††p < 0.001 MSK-CA vs MSK-LQ; ††p < 0.01 MSK-CA vs MSK-LQ; †p < 0.05 MSK-CA vs MSK-LQ; ###p < 0.001 MSK-RR vs MSK-LQ; ##p < 0.001 MSK-RR vs MSK-LQ; and #p < 0.05 MSK-RR vs MSK-LQ. CA chronically active, LQ long quiescence, MSK musculoskeletal, PGA Physician Global Assessment, RR relapsing–remitting, SELENA SLEDAI Safety of Estrogens in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index